The United States Food and Drug Administration (USFDA) approved Uptravi (Selexipag) for treatment of pulmonary arterial hypertension (PAH) in adults. Uptravi has received orphan drug designation. Uptravi is to be commercialized by Actelion-Pharmaceuticals.
Uptravi is an oral IP prostacyclin receptor antagonist that dilates blood vessels and lower blood pressure in pulmonary blood vessels.
Long-term clinical studies were conducted that involved 1,156 PAH patients who were assigned to receive Uptravi treatment for 1.4 years. Uptravi treatment has shown to reduce hospitalization risk and disease progression in PAH patients, compared with placebo group.
Some of the common adverse events of Uptravi are vomiting, flushing, jaw pain, headache, diarrhea, nausea, pain in the extremities and myalgia.